"defining the safety and efficacy of posterior tibial nerve stimulation in children(positron-c)"
Ended Awarded Last action
- Contract number
- 75N94021F00002
- Awardee
-
Duke University UEI TP7EK8DZV6N5
- Awarding agency
-
National Institute of Child Health and Human Development
National Institutes of Health, Department of Health and Human Services
- Obligated
- $862,140
Award facts
- Contract value 100% obligated
- $862,140.15 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Durham, NC 27705, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$1,226,913 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $2,089,053 |
About this award
Duke University's Office of Research Administration was awarded a delivery order valued at $862,140.15 under the Best Pharmaceuticals for Children Act (BPCA) Pediatric Trials Network (PTN) program to define the safety and efficacy of posterior tibial nerve stimulation in children (POSITRON-C study). The award, issued on September 13, 2021, by the National Institute of Child Health and Human Development (NICHD), represents a Cost No Fee contract type with an ultimate completion date of September 5, 2025. The work will be performed in Durham, North Carolina, with no set-aside designation applied to this competitive award.
This delivery order is part of Duke University's larger Indefinite Delivery/Indefinite Quantity (IDIQ) contract with the National Institute of Allergy and Infectious Diseases valued at up to $136.6 million for evaluation and testing services for vaccines and biologics. The POSITRON-C study supports the BPCA-PTN program's mission to advance pediatric drug development through rigorous clinical trials. Duke University, as a leading research institution with extensive experience managing complex federal research programs, is leveraging its multidisciplinary capabilities and clinical trial infrastructure to execute this pediatric medical device evaluation study aligned with the government's cost efficiency initiatives.
Quick answers
Who was awarded contract 75N94021F00002?
75N94021F00002 was awarded to Duke University by National Institute of Child Health and Human Development (National Institutes of Health) on September 13, 2021.
How much is contract 75N94021F00002 worth?
The government has obligated $862,140 on 75N94021F00002.
Is contract 75N94021F00002 an order under another contract?
Yes. 75N94021F00002 is a delivery order under 75N94018D00003, an indefinite delivery contract.
Was contract 75N94021F00002 competed?
The extent of competition for 75N94021F00002 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award